266
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Latent tuberculosis among injection drug users in a methadone maintenance treatment program, Taipei, Taiwan: TSPOT.TB versus tuberculin skin test

, , , , , , , , , , , , & show all
Pages 504-511 | Received 11 Oct 2012, Accepted 15 Jan 2013, Published online: 15 Jun 2013

References

  • Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220–6.
  • Corbett EL, De Cock KM. Tuberculosis in the HIV-positive patient. Br J Hosp Med 1996;56:200–4.
  • Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, et al. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1993;119:185–93.
  • Mathur ML, Chaudhary RC. Increased risk of tuberculosis in opium addicts. Indian J Med Sci 1996;50:365–7.
  • Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 2003;16:209–19.
  • Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003;157:467–71.
  • Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008;372:1733–45.
  • Frothingham R, Stout JE, Hamilton CD. Current issues in global tuberculosis control. Int J Infect Dis 2005;9: 297–311.
  • Burgos JL, Kahn JG, Strathdee SA, Valencia-Mendoza A, Bautista-Arredondo S, Laniado-Laborin R, et al. Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico. Int J Tuberc Lung Dis 2009;13:962–8.
  • Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340–54.
  • Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761–76.
  • Diagnostic standards and classification of tuberculosis in adults. and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376–95.
  • Revised guidelines for HIV counseling, testing, and referral. MMWR Recomm Rep 2001;50:1–57.
  • Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics 1977;33:363–74.
  • Lee SS, Chou KJ, Su IJ, Chen YS, Fang HC, Huang TS, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB Gold, ELISPOT, and tuberculin skin test. Infection 2009;37:96–102.
  • Chiu HY, Hsueh PR, Tsai TF. Clinical experience of QuantiFERON -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011;164:553–9.
  • Grimes CZ, Hwang LY, Williams ML, Austin CM, Graviss EA. Tuberculosis infection in drug users: interferon-gamma release assay performance. Int J Tuberc Lung Dis 2007;11: 1183–9.
  • Garfein RS, Lozada R, Liu L, Laniado-Laborin R, Rodwell TC, Deiss R, et al. High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico. Int J Tuberc Lung Dis 2009;13:626–32.
  • Portu JJ, Aldamiz-Etxebarria M, Agud JM, Arevalo JM, Almaraz MJ, Ayensa C. Tuberculin skin testing in intravenous drug users: differences between HIV-seropositive and HIV-seronegative subjects. Addict Biol 2002;7:235–41.
  • Rusen ID, Yuan L, Millson ME. Prevalence of Mycobacterium tuberculosis infection among injection drug users in Toronto. CMAJ 1999;160:799–802.
  • Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009;48:72–82.
  • Chiang CY, Hsu CJ, Hsu PK, Suo J, Lin TP. Pulmonary tuberculosis in the Taiwanese prison population. J Formos Med Assoc 2002;101:537–41.
  • Brassard P, Bruneau J, Schwartzman K, Senecal M, Menzies D. Yield of tuberculin screening among injection drug users. Int J Tuberc Lung Dis 2004;8:988–93.
  • Story A, Murad S, Roberts W, Verheyen M, Hayward AC. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 2007;62:667–71.
  • Pablos-Mendez A, Knirsch CA, Barr RG, Lerner BH, Frieden TR. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997;102:164–70.
  • Scholten JN, Driver CR, Munsiff SS, Kaye K, Rubino MA, Gourevitch MN, et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis 2003; 37:1686–92.
  • O’Connor PG, Shi JM, Henry S, Durante AJ, Friedman L, Selwyn PA. Tuberculosis chemoprophylaxis using a liquid isoniazid–methadone admixture for drug users in methadone maintenance. Addiction 1999;94:1071–5.
  • Garfein RS, Laniado-Laborin R, Rodwell TC, Lozada R, Deiss R, Burgos JL, et al. Latent tuberculosis among persons at risk for infection with HIV, Tijuana, Mexico. Emerg Infect Dis 2010;16:757–63.
  • Howard AA, Klein RS, Schoenbaum EE, Gourevitch MN. Crack cocaine use and other risk factors for tuberculin positivity in drug users. Clin Infect Dis 2002;35: 1183–90.
  • Jiang W, Shao L, Zhang Y, Zhang S, Meng C, Xu Y, et al. High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area. BMC Immunol 2009;10:31.
  • Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011;56:230–8.
  • Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection— United States, 2010. MMWR Recomm Rep 2010;59: 1–25.
  • Canadian Tuberculosis Committee. Updated recommendations on interferon gamma release assays for latent tuberculosis infection. Can Commun Dis Rep 2010;36:1–21.
  • Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968–75.
  • Kimura M, Converse PJ, Astemborski J, Rothel JS, Vlahov D, Comstock GW, et al. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis 1999;179: 1297–300.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.